Pharma Focus Europe

DiaCarta Receives CE-IVD Mark for Its SARS CoV-2 Flu A/B Combo Test

Thursday, July 21, 2022

DiaCarta Inc., precision molecular diagnostics company, CE-IVD mark, QuantiVirus™ SARS-CoV-2 & Flu A/B Test, Real-Time PCR test, qualitative detection, nucleic acid, SARS-CoV-2, Influenza viruses, nasopharyngeal swab, saliva, COVID-19, Influenza, Positive Predictive Agreement (PPA), Negative Predictive Agreement (NPA), commercialize, CE marking, medical devices, FDA EUA, 510k submissions, SARS-CoV-2 variants, BA 5 sub-variant, multiplex test, simultaneous detection, clinical symptoms, Dr. Aiguo Zhang, CEO, President.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva